Your browser doesn't support javascript.
loading
A transatlantic perspective on the integration of immuno-oncology prognostic and predictive biomarkers in innovative clinical trial design.
Morfouace, M; Hewitt, S M; Salgado, R; Hartmann, K; Litiere, S; Tejpar, S; Golfinopoulos, V; Lively, T; Thurin, M; Conley, B; Lacombe, D.
Affiliation
  • Morfouace M; EORTC Headquarters, Brussels, Belgium. Electronic address: marie.morfouace@eortc.be.
  • Hewitt SM; Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda MD, USA.
  • Salgado R; EORTC Pathobiology Group, Breast Cancer Translational Research Laboratory, Jules Bordet Institute, Brussels, Belgium; Translational Breast Cancer Genomic and Therapeutics Laboratory, Peter Mac Callum Cancer Center, Victoria, Australia, Australia; Department of Pathology, GZA, Antwerp, Belgium.
  • Hartmann K; EORTC Headquarters, Brussels, Belgium.
  • Litiere S; EORTC Headquarters, Brussels, Belgium.
  • Tejpar S; Molecular Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium.
  • Golfinopoulos V; EORTC Headquarters, Brussels, Belgium.
  • Lively T; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, DHHS,9609 Medical Center Drive, Bethesda, MD 20892 USA.
  • Thurin M; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, DHHS,9609 Medical Center Drive, Bethesda, MD 20892 USA.
  • Conley B; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, DHHS,9609 Medical Center Drive, Bethesda, MD 20892 USA.
  • Lacombe D; EORTC Headquarters, Brussels, Belgium.
Semin Cancer Biol ; 52(Pt 2): 158-165, 2018 10.
Article in En | MEDLINE | ID: mdl-29307568
ABSTRACT
Immuno-therapeutics aim to activate the body's own immune system against cancer and are one of the most promising cancer treatment strategies, but currently limited by a variable response rate. Biomarkers may help to distinguish those patients most likely to respond to therapy; they may also help guide clinical decision making for combination therapies, dosing schedules, and determining progression versus relapse. However, there is a need to confirm such biomarkers in preferably prospective clinical trials before they can be used in practice. Accordingly, it is essential that clinical trials for immuno-therapeutics incorporate biomarkers. Here, focusing on the specific setting of immune therapies, we discuss both the scientific and logistical hurdles to identifying potential biomarkers and testing them in clinical trials.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Biomarkers, Tumor / Neoplasms Type of study: Prognostic_studies / Risk_factors_studies Limits: Animals / Humans Language: En Year: 2018 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Biomarkers, Tumor / Neoplasms Type of study: Prognostic_studies / Risk_factors_studies Limits: Animals / Humans Language: En Year: 2018 Type: Article